Home|English|İ
Home
Investment Philosophy
Portfolio
News And Events
Team
Contacts
Related Links
News And Events
  May 14, 2012
  Cornerstone Therapeutics to Acquire EKR Therapeutics for $150 million dollars
  July 14, 2011
  EKR Therapeutics Featured on the Global Learning Series Television Series for Fall and Winter Season
  September 28, 2010
  New Study Demonstrates Ready-to Use Cardene I.V. More Effective than Labetalol for Immediate Control of Blood Pressure in Emergency Room Patients
  February 16, 2010
  EKR Therapeutics Receives Two Additional Patents for Ready-to-Use Cardene I.V. Bags, Providing Substantial Intellectual Property Protection Through 2027
  November 20, 2009
  EKR Therapeutics Named Private Company of the Year By New Jersey Technology Council
  September 9, 2009
  John E. Bailye, Dendrite Founder, Joins EKR Therapeutics as Executive Chairman; Expansion in Board Signifies Key Growth Milestone
  September 3, 2009
  EKR Therapeutics to Present at the Thomas Weisel Partners 2009 Annual ealthcare Conference
  June 25, 2009
  Howard Weisman, Chairman & CEO of EKR Therapeutics, Named Ernst & Young Entrepreneur Of The Year?2009 Award Winner For The New Jersey Pharmaceutical Industry
  March 12, 2009
  EKR Therapeutics to Present at the Cowen and Company 29th Annual Health Care Conference
  October 28 , 2009
  EKR Therapeutics Receives Notice of Patent Allowance for Ready-to-Use Cardene ® I.V. Bags, a Specialty Product Line for Treating Acute Hypertension in Emergency and Critical-Care Settings
  January 13 , 2009
  EKR Therapeutics was invited to present at the 27th Annual J.P. Morgan Healthcare Conference
  August 1, 2008
  ESP Portfolio Company -- EKR Therapeutics Receives Approval for Ready-to-Use Intravenous Bags of Cardene ® I.V.
  March 10, 2008
  ESP Equity further increases its investment stake in EKR Therapeutics , Inc. in the lastest $145 million financing General Partners Howard Weisman and S.Douglas Sheldon both serve on the board

  February 4, 2008
EKR Therapeutics and PDL sign asset purchase agreement for cardiovascular products
  AUGUST 16, 2007
  ESP Equity Partners continues its support for EKR Therapeutics in Series C Financing
  AUGUST 15, 2007
 

EKR Therapeutics Raises Over $13 Million in a Series C Financing Round From New and Existing Investors

EKR Therapeutics Achieves Key Growth Milestone with the Acquisition of Rights from Pacira Pharmaceuticals to DepoDur a Novel Extended -Release Opioid Analgesic for Post Operative Pain

  JUNE 27, 2006
  ESP Pharma Founder Launches EKR Therapeutics with Financing Led by NewSpring Capital and ESP Equity Partners
  MAY 3, 2005
  ESP co-founders open private equity firm ESP , LLC..

 

Home | Contacts | Support | Related Links Copyright ©2010 ESP Equity Partners LLC